Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC

Rezultati

Naziv:	Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC
Autori :	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20)
Godina:	2020
Publikacija:	JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN:	2051-1426 Journal for ImmunoTherapy of Cancer Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 8 str. A1-A1
DOI:	10.1136/LBA2019.1
WoS-ID:	000540356400002
URI:	https://enauka.gov.rs/handle/123456789/811779
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

6
OpenCitations

6
WEB OF SCIENCE^TM

Alt metrika

Dimensions

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.